ライフサイエンスコーパス: LH-RH

1 LH-RH receptor-positive (MCF-7) and -negative (UCI-107)

2 The components of AN-207 (LH-RH analogue carrier and cytotoxic radical AN-201 as s

3 We stably transfected COS cells with a LH-RH receptor (LH-RH-Rc) mammalian expression vector an

4 152 can be regulated by the number of active LH-RH receptors on cancer cells.

5 sing hormone (LH-RH), is more potent against LH-RH receptor-bearing cancers and produces less periphe

6 increase in medium concentrations of AA and LH-RH induced by high [K(+)], suggesting that NO mediate

7 creased medium concentrations of both AA and LH-RH.

8 ting that NO mediates release of both AA and LH-RH.

9 tagonists suppress gonadotroph functions and LH-RH receptor (LH-RH-R) production are incompletely und

10 reas CP hydrolysis gives rise to CCK5-GR and LH-RH-GK, both of which are susceptible to the dipeptidy

11 no acids from the C-terminus of CCK5-GRR and LH-RH-GKR, but only CP is responsible for converting dia

12 (10(-5) to 10(-3) M) had no effect on basal LH-RH release but completely blocked high [K(+)]- and ni

13 reated with AN-207 was partially restored by LH-RH antagonist.

14 effects on the gonadotroph cells containing LH-RH receptors and is less toxic for other cells.

15 From these DOX containing LH-RH hybrids, intensely potent analogs with daunosamine

16 This study demonstrates that the cytotoxic LH-RH analog AN-207 exerts highly selective effects on t

17 Thus, cytotoxic LH-RH agonist containing DOX (AN-152) can be converted i

18 we applied an in vitro method to desaturate LH-RH receptors by chaotropic agents such as manganous c

19 racting the stimulatory effect of endogenous LH-RH.

20 , was increased in stable cells that express LH-RH-Rc compared with parental cells.

21 lent concentrations, in COS cells expressing LH-RH-Rc but not in parental COS cells.

22 d down-regulation of pituitary receptors for LH-RH and not merely an occupancy of binding sites.

23 ecreased the level of membrane receptors for LH-RH by 83% (P < 0.01) after 7 days, and 86% (P < 0.01)

24 e number of pituitary membrane receptors for LH-RH in a time-dependent manner with the nadir occurrin

25 the binding characteristics of receptors for LH-RH in membrane fractions from rat anterior pituitarie

26 nd subcellular localization of receptors for LH-RH in rat pituitaries.

27 eatment of tumors that possess receptors for LH-RH such as prostatic, mammary, ovarian, and endometri

28 NA expression of the pituitary receptors for LH-RH.

29 e mRNA expression of pituitary receptors for LH-RH.

30 he conjugates to rat pituitary receptors for LH-RH.

31 ment, the concentration of binding sites for LH-RH in the nuclei of rat pituitaries was significantly

32 Higher LH-RH receptor concentrations coincided with elevated se

33 Lys6] luteinizing hormone-releasing hormone (LH-RH) (AN-207), was demonstrated to be less toxic than

34 og of luteinizing hormone-releasing hormone (LH-RH) containing DOX, at 0.3 mg/ml is 19.49 +/- 0.74 mi

35 ts of luteinizing hormone-releasing hormone (LH-RH) leads to down-regulation of pituitary LH-RH recep

36 on of luteinizing hormone-releasing hormone (LH-RH) release from medial basal hypothalamic explants b

37 07 of luteinizing hormone-releasing hormone (LH-RH), consisting of an intensely potent derivative of

38 Lys6]-luteinizing hormone-releasing hormone (LH-RH), is more potent against LH-RH receptor-bearing ca

39 ts of luteinizing hormone-releasing hormone (LH-RH), unlike the LH-RH agonists, suppress gonadotropin

40 gs of luteinizing hormone-releasing hormone (LH-RH).

41 tion in cycling rats with normal hypophysial LH-RH environment.

42 RH, did not cause any significant changes in LH-RH-R mRNA level.

43 ocked high [K(+)]- and nitroprusside-induced LH-RH release.

44 -pyrrolinodoxorubicin conjugated to [D-Lys6] LH-RH, exerted through induction of apoptosis and modula

45 p of the D-Lys side chain of agonist [D-Lys6]LH-RH or antagonistic analog AC-D-Nal(2)-D-Phe(4Cl)-D-Pa

46 nd on the cellular uptake of AN-152, [D-Lys6]LH-RH, or doxorubicin was assessed by the 3-(4,5-dimethy

47 N-201) conjugated to carrier agonist [D-Lys6]LH-RH.

48 x can affect the concentration of measurable LH-RH binding sites, we applied an in vitro method to de

49 time intervals, we could not detect occupied LH-RH binding sites.

50 esults show that the percentages of occupied LH-RH receptors at 1, 3, and 6 h after administration of

51 Our results indicate that administration of LH-RH antagonist Cetrorelix produces a marked down-regul

52 ) is a modern, potent antagonistic analog of LH-RH.

53 These highly potent cytotoxic analogs of LH-RH were designed as targeted anti-cancer agents for t

54 tive group to yield cytotoxic derivatives of LH-RH analogs containing DOX.

55 n the superfusion system, which is devoid of LH-RH, did not cause any significant changes in LH-RH-R

56 Thus, the effect of LH-RH antagonists is similar to that of the LH-RH agonis

57 this study was to investigate the effects of LH-RH antagonist cetrorelix on the binding characteristi

58 The number of LH-RH binding sites in the nuclear pellet was increased

59 The down-regulation of LH-RH binding sites induced by Cetrorelix was accompanie

60 ults demonstrate that the down-regulation of LH-RH receptors on the cell membranes of rat pituitaries

61 in AA in the medium but also the release of LH-RH.

62 ansmitter that blocks NOergic stimulation of LH-RH release by chemically reducing the NO released by

63 In addition, survival of LH-RH-Rc positive cells treated with AN-207 was partiall

64 rnalization and subcellular translocation of LH-RH receptors.

65 xperimental systems with different pituitary LH-RH environments.

66 ased the concentration of mRNA for pituitary LH-RH-R by 72.6% in OVX rats, but only by 32.9% in norma

67 LH-RH) leads to down-regulation of pituitary LH-RH receptors.

68 trorelix on the mRNA expression of pituitary LH-RH-R and luteinizing hormone (LH) secretion in three

69 effects on the gene expression of pituitary LH-RH-R by counteracting the stimulatory effect of endog

70 ase occurred in the mRNA levels of pituitary LH-RH-R in ovariectomized (OVX) rats with high pituitary

71 ncreases in the mRNA expression of pituitary LH-RH-R in rats after 11 and 21 days, respectively.

72 esaturation, demonstrated that rat pituitary LH-RH receptors were significantly (P < 0.01) down-regul

73 ss gonadotroph functions and LH-RH receptor (LH-RH-R) production are incompletely understood.

74 transfected COS cells with a LH-RH receptor (LH-RH-Rc) mammalian expression vector and examined the e

75 C-160 have been shown previously to regulate LH-RH receptors through phosphorylation.

76 cid neurotransmitter glutamic acid, releases LH-RH by releasing NO.

77 nitroprusside, which releases NO, stimulated LH-RH release and decreased the concentration of AA in t

78 Our findings indicate that LH-RH antagonists exert their inhibitory effects on the

79 Two weeks after administration, the LH-RH-stimulated LH release in vivo entirely normalized

80 N-207, as evidenced by a 63% decrease in the LH-RH-stimulated release of LH in vitro.

81 AA (10(-5) to 10(-3) M) inhibited the LH-RH-releasing action of NMDA.

82 LH-RH antagonists is similar to that of the LH-RH agonists, but the mode of action of antagonists is

83 ormone-releasing hormone (LH-RH), unlike the LH-RH agonists, suppress gonadotropins and sex steroid s

84 d (OVX) rats with high pituitary exposure to LH-RH, but there was a significant 23.2% reduction in cy

85 Clinically used LH-RH antagonists partially inhibited apoptotic Bax expr

86 The mechanisms through which LH-RH antagonists suppress gonadotroph functions and LH-

87 conjugate was: (a) specific for cancers with LH-RH receptors; (b) up-regulated by EGF; (c) down-regul

88 The conjugation of DOX with LH-RH analogs was performed by using N-(9-fluorenylmetho

89 single injection or prolonged treatment with LH-RH antagonist also decreased the mRNA expression of p